<SEC-DOCUMENT>0001193125-24-010234.txt : 20240118
<SEC-HEADER>0001193125-24-010234.hdr.sgml : 20240118
<ACCEPTANCE-DATETIME>20240118163053
ACCESSION NUMBER:		0001193125-24-010234
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240118
FILED AS OF DATE:		20240118
DATE AS OF CHANGE:		20240118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		24542216

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d620838d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of January, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment of Director </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of
Director; Appointment of Chairman </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;15, 2024, the Board of Directors (the &#147;Board&#148;) of Kazia Therapeutics
Limited (the &#147;Company&#148;) appointed Robert Apple to the Board. On January&nbsp;18, 2024, the Company issued a Press Release titled, &#147;Kazia Continues Board Renewal with Two New Appointments.&#148; A copy of this release is furnished as
Exhibit&nbsp;99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Apple brings more than 25 years of senior leadership experience in
the pharma industry to the Company, including 16 years with Antares Pharma, Inc. (&#147;Antares&#148;), where he served as Senior Vice President, Chief Financial Officer, Corporate Secretary, President, and Chief Executive Officer. Prior to Antares,
Mr.&nbsp;Apple was Chief Operating and Financial Officer at InKine Pharmaceutical Company. Mr.&nbsp;Apple served on the Board of Directors at Antares from 2016 until May 2022. Mr.&nbsp;Apple has also served on the Boards of, InKine Pharmaceutical,
PaxMedica Inc, and Kerathin Inc. He also held prior roles at Genaera Corporation, Liberty Technologies, and Arthur Andersen&nbsp;&amp; Company. Mr.&nbsp;Apple has a Bachelor of Accounting from Temple University, Philadelphia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board also appointed Bryce Carmine to the role of Chairman of the Board, effective as of January&nbsp;10, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Carmine joined the Board as a Director in 2015, following a long and distinguished career at Eli Lilly&nbsp;&amp; Co.
(&#147;Lilly&#148;) where he served as Executive Vice President, and also as President for Lilly <FONT STYLE="white-space:nowrap">Bio-Medicines.</FONT> Prior to this, he led the Global Pharmaceutical Sales and Marketing division and was a member of
the company&#146;s Lilly&#146;s Executive Committee. Mr.&nbsp;Carmine previously held a series of product development portfolio leadership roles at Lilly culminating when he was named President, Global Pharmaceutical Product Development, with
responsibility for the entire late-phase pipeline development across all therapeutic areas for Lilly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by
reference the information contained herein, including Exhibit 99.1, except for the quotes of Dr.&nbsp;John Friend in Exhibit 99.1, into the Company&#146;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-259224</FONT> and <FONT STYLE="white-space:nowrap">333-276091).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated January&nbsp;18, 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 18&nbsp;January 2024</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d620838dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g620838g97f50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PRESS RELEASE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18&nbsp;January 2024 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA CONTINUES BOARD
RENEWAL WITH TWO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEW APPOINTMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18</B><B></B><B>&nbsp;January 2024</B> &#150; Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to
announce the appointment of pharma industry executive, Mr.&nbsp;Robert Apple to Kazia&#146;s Board of the Directors (the &#147;Board&#148;) as a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc.
(&#147;Antares&#148;) as Senior Vice President, Chief Financial Officer and Corporate Secretary,&nbsp;and went on to serve as President and Chief Executive Officer from 2016 until its acquisition by Halozyme Therapeutics in 2022. Mr.&nbsp;Apple also
served on the Board of Directors at Antares from 2016 until May 2022. He previously served on the Boards of Directors of InKine Pharmaceutical, PaxMedica Inc., and Kerathin Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to joining Antares, Mr.&nbsp;Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical. He also held prior roles at Genaera
Corporation, Liberty Technologies, and Arthur Andersen&nbsp;&amp; Company. He holds a B.A. degree in accounting from Temple University, Philadelphia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
a further renewal of the Board, <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Mr.&nbsp;Bryce Carmine has been appointed Chairman. Mr.&nbsp;Carmine joined the Kazia Board as a Director in 2015, following a long and distinguished
career at Eli Lilly&nbsp;&amp; Co. (&#147;Lilly&#148;) where he served as Executive Vice President, and also as President for Lilly <FONT STYLE="white-space:nowrap">Bio-Medicines.</FONT> Prior to this, he led the Global Pharmaceutical Sales and
Marketing division and was a member of the Lilly&#146;s Executive Committee. Mr.&nbsp;Carmine previously held a series of product development portfolio leadership roles at Lilly culminating when he was named President, Global Pharmaceutical Product
Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Lilly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenting on the Board
appointments, Kazia&#146;s CEO Dr.&nbsp;John Friend said: &#147;We are delighted that Bryce has accepted the role of Chairman and that Bob has agreed to join the Board. With deep biopharmaceutical leadership experience across finance, business
development, and commercial operations, Bob&#146;s expertise and business acumen will be extremely valuable. His experience, combined with that of the other directors will ensure further oversight and stewardship of the Kazia business, as the
Company is poised to enter its next phase of growth.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cherie Hartley </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR Department </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +61 418 737 020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: Cherie.hartley@irdepartment.com.au
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g620838g48h22.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase II study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study, GBM AGILE, is
completed, with final data expected in first half of CY2024. Other clinical trials are ongoing in brain metastases, DMGs, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US Food and Drug Administration (US FDA) in February 2018, and Fast Track Designation
for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July
2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical
data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. A Phase I study in advanced solid tumors commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the Company&#146;s corporate governance strategy, management team, and the timing or results of any clinical trials. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends
affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and
preclinical trials and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and
uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the United States Securities and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exchange Commission (&#147;SEC&#148;), and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g620838g48h22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g620838g48h22.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M4,IB#CS%4,5SR <X/Z'\J 'T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MT)M; TF+_9=AY]O/]C@\ZW79"_EC,:^@/847860^WL;2TEFDMK:*%YVWRLB
M%SZGUHN.U@:PM&MY;=K:(PS$M(A0%7)ZDCO1<+!%8VD%E]BBMHDM=I3RE4!<
M'J,47"W0L4@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MX=MYC=$S2JTT\<ZLN/W;(VY<<<C=D\^IHYAV+2:>WFP337,DLD3L^2  <KC
M'8"E<+%=-*N8+@7$-[NF;RXW>1!DQJ2<<=6Y(R?7\RX6)+S2GN-5M]1@NC!-
M#"\(&P,"K%2?_0!0G96"VMQ\6F&"]DFCNI%BDE\YX@!@MMV]>N. <>OY47"Q
M!'H,4%O)'%/(KFY^TJ^ =A[#'ICCZ47"Q9AT_P NX@G>XDEDA21,MCYM[*Q_
M+: /:BX6(1I+_;KJ9[D2Q76!)%)$&!0#&S/IR?S/K1<+$-MX=LM+NY;K2;6V
MLY)A&C>7"J@(K9;&!U(./P'I3YF]Q62V+UW:33R*\%[);G:4(4!E(/?![CU_
MG20RD/#\49"0W,L=L1$'AP"&\O 7G&1PH!^G:G<+$EKHD5I="1)Y#"DTDZ0D
M#"R/G<<]<?,W'O\ 3"N%K"3Z.TTUU_I;+;W4BR2Q!!DX55QGL"$'ZT7"P1Z&
MD5Z)UN9/+%P]P(R!C>R%3SUQR<?_ *L%PL0R^&XWMX(H[N6,QV?V(L%4EDP/
M4<'C_/%/F%RDT&AQ022N)G)DNEN3D#@A N/I\M*X[&99:/<7$LT%Q'<6]M';
MFWCWLC ?/D;,=0 H^\/3WJF["2-&UT%+>^>\>YDEFDN?M+$@ ;O*\K'';%*_
M0=AK^'+:4LDTLCP?OMD? V&7.XY[]3CTS1S!8LVFE_9KBYNFN'ENKA%C:0@#
M"KG: !_O$_C2N%K%&T\):98?8Y;6".*\MV#&Z$:^;+P0VYL9.[)S3YFQ<J18
MBT&*"W>.*>17-S]I5\ [#V7'ICCZ4KCL*^B"6*99KR:5Y8)86=\9PYR<<<8Q
MP*+A8:-"564+=2"+S(I63:/F9 H'/IA%X]J=PL+'I=W9V0@L[]LQ1>3 )%&U
M!Q@G'WB ./\ Z]*X6L6KNQ>XE@FBNI()H=P#* 0P.,@@]>@H3L%BC/HR@Z3"
MF]TMIS([DC)&">?J^T\>E.XK!<>'8[BZCE-U*L<4LDR1 # 9T96YZ_Q$_C1S
M!85_#T377VE;B1)1!#"I ''E,S _CN(-%PL,U'1I+W[!'--+,%NO-E?A?E"D
M[<?W20HQ0G8&C5N+5;B:UD9B#;RF0 =SL9<?^/&EL495KX:BL/--I=S1DW!G
MC!P1'E2NW'=>3QV_"GS7)Y;$UQH,-UH\FG2SR$22&1Y  &)+;C[#/(^AI7L[
MCMI8L?V7%_;G]J[V\WR/)V?P]<Y^O:B^E@MK<9+ITSZK]NCO-A\L1A#&&"C.
M3CTSQGZ#THOI8+:C%T1!."UQ(]NLKS+"0,*SA@W.,X^=N/>BX6(H/#L45H;:
M2ZFEC6W^S1$A08T[=!R>!R?0>^7<5BU%IICM[Q3<NT]UDO-M (.T*,#V %*X
M[%6T\*Z1ITUM+I]E#:20 J7BC4-(I4@ACU/8_44^9O<7*EL,M?#OV25IH[^;
MS/L\5NI*KPD9) (QSG<<_P!*.8+6)[+0XK!;-;>=P+99$&X [E=@Q'MR!C'0
M<4F[C2L0R^&XWMX8H[N6,QV?V(L%4EDP/4<'C_/%/F%RDUOH4-O=-.)G)-R;
MC'N8O+Q],<TKCL/TW1QIL@87#RA8$@16 &U%SCIU//6ANX)6-*D,S-7N[^R1
M9;5+=XBR(?,+ Y9@O;MR*SG*4=4=6'ITJCY9MWUV\E<NP-,ML&N_+649+>63
MM'Y^U6KVU,)\G-[FWF5KW4A;Q6K6Z),UT^V,M)L3&TMDM@\84]O2J2,VQC:G
M,DFFI)8LANV*.2XQ$0C-C_:^[_GI18+D]Y<74+(MM:I+D%G>27RT0#'4X)R<
M^G8T("!M48Z;97,-OF6\V>7$[[<%EW<G!Q@ ]J+:A<K77B![72);K['YEU'(
M\7V=)."RY)^8CIM!.<?AFG;45[(L3ZC>0S6H%I"T-Q(J*?/(?D9)V[,< ,>O
M:E8=Q;;4;F2^CM[BR$ F1W3][N8!2!\PQ@9W#H318+B7&K-#K=IIR6QD28D2
M3;\",[691C')(0^F./6BVEPOK8B36IW65/L/EW"W(MTC>4#.4#Y) ..">F>E
M.P7%?6I8[6.0V1+_ &D6\H60;8R7"9R>3U!''Y46"YKU(S,NKN__ +3^QV26
MYVPB1FF+#J2,#'TK-RES6B=5.G2]ESU&][:%R65HC;J7B5I'VD,3S\I.%]^/
MR!K1'*[7T*,_B'3DTNXOK>YBN$AA,V(WSN&#C\\8S3L[V%=6)X=3MOW,,]U
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M4 % !0 4 % !0 4 -1UD7<C!ATR#FFTUN)-/5#J0PH * "@! H4D@ $G)]Z
M%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H I3WKP:I;6S(/*F5CO]&'./RK6,$X.75&$ZKC5C#H
M[_@9\.O32:?=3FW E0KY2<_.&.%-;/#I32OIU^1S1Q<G3E*VJM;SOL6Y-2>
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M><I<ETW:^GZE1IKR7PY/)<^6Y\W";2<G$N,'\N*T48*LE'^M#%RJ2PS<^_\
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M)N%UYV><8W9Q]:OVRY^;RL9_5I>SY+];_B;5<IW!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 ! (((R/2@!%58T5$4*JC  & !0W?5B2
M25D+0,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
CH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g620838g97f50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g620838g97f50.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M:N9X[$5H5N6+LD==9222V%O),NV1XU+#T.*\Z:2DTCVJ4G*"<M[$]0:!0 4
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M%[FIIE[9:]8Q7\<*GDC$B@LA'45O3J\T;Q9Y^*PGL*O)42;1SVO7&LVVMO\
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M7VD3+V<A?^%2^*O^>%N/^VXH]I$/9R/?8E,<*(>JJ :YCH'T >+?\*T\1?\
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L "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
